Study of new drugs for fatty liver with scarring
Treatments studied
Part of Digestive system clinical trials.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have at least 8% fat in your liver.
- Your liver scarring (ELF) score must be between 9 and 10.8 on a blood test.
- Your liver stiffness (on a FibroScan) must be between 10 and 20 kPa.
- You cannot have other types of liver disease besides MASLD (fatty liver linked to metabolism).
- Your body mass index (BMI) must be 25 or higher (overweight or obese).
- You cannot have lost more than 11 pounds in the last 3 months.
- Your blood sugar control (HbA1c) must be 10% or lower, and you cannot have type 1 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests a new treatment called ALN-CIDEB for adults with a liver condition called MASLD, where fat builds up in the liver. The treatment aims to reduce liver fat and improve liver health.
This study tests whether a diabetes medicine called henagliflozin can reduce liver scarring in people who have both fatty liver disease (MASLD) and type 2 diabetes. If you qualify, you may receive the study drug and help researchers learn if it can improve liver health.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
This trial tests a digital diet and exercise program to help reduce liver scarring in people with fatty liver disease. You'll use an app or online tool to follow healthy eating and activity routines, which may slow or reverse liver damage.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.